OQS
CBIO icon

Occudo Quantitative Strategies’s Crescent Biopharma CBIO Stock Holding History

Occudo Quantitative Strategies’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-102
Closed -$38K – 822
2020
Q4 		$38K Buy
+102
New +$35.7K 0.01% 622

Other funds holding CBIO

BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Occudo Quantitative Strategies's CBIO Position: Q1 2021 in Review

Occudo Quantitative Strategies sold out of Crescent Biopharma (CBIO) in Q1 2021, closing a stake of 102 shares — an estimated $38K sold.

Occudo Quantitative Strategies first reported a position in CBIO in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 78 funds tracked by Wall St. Rank hold CBIO as of Q1 2021.

  • Occudo Quantitative Strategies reported no remaining Crescent Biopharma position as of Q1 2021 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 102 Crescent Biopharma shares in Q1 2021, an estimated $38K.
  • Occudo Quantitative Strategies first reported a position in Crescent Biopharma in Q4 2020 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Crescent Biopharma position peaked at $38K in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2021.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2021, filed 14 May 2021.